University of Wisconsin–Madison

Reading List

Course: PSYCH 711 – CURRENT TOPICS IN PSYCHOLOGY: Wisconsin Symposium on Emotion

Huda Akil, Ph.D.

Elissa Epel, Ph.D.

  1. New models of Stress: Epel, E. S. et al. More Than a Feeling: A unified view of stress measurement for population scienceFront Neuroendocrinol 49, 146–169 (2018).
  2. Epel, E. & Prather, A. Stress, Telomeres, and Psychopathology: Toward a Deeper Understanding of a Triad of Early AgingAnnual Review of Clinical Psychology 14, (2018).
  3. Meditation, Stress Processes, and Telomere BiologyCurrent Opinion in Psychology 28, pp–pp (2019).
  4. Crosswell, Coccia, & Epel. Mind Wandering and Stress: When You don’t Like the Present Moment. (2018)
  5. [TBD]

George F. Koob, Ph.D.

 

David R. Rubinow, M.D.

1) Differential behavioral effects of gonadal steroids in women with and in those without premenstrual syndrome.  Schmidt PJ, Nieman LK, Danaceau MA, Adams LF, Rubinow DR. N Engl J Med. 1998 Jan 22;338(4):209-16.

2) Effects of Estradiol Withdrawal on Mood in Women With Past Perimenopausal Depression: A Randomized Clinical Trial. Schmidt PJ, Ben Dor R, Martinez PE, Guerrieri GM, Harsh VL, Thompson K, Koziol DE, Nieman LK, Rubinow DR. JAMA Psychiatry. 2015 Jul;72(7):714-26.

3) Premenstrual Dysphoric Disorder Symptoms Following Ovarian Suppression: Triggered by Change in Ovarian Steroid Levels But Not Continuous Stable Levels. Schmidt PJ, Martinez PE, Nieman LK, Koziol DE, Thompson KD, Schenkel L, Wakim PG, Rubinow DR. Am J Psychiatry. 2017 Oct 1;174(10):980-989.

4) The ESC/E(Z) complex, an effector of response to ovarian steroids, manifests an intrinsic difference in cells from women with premenstrual dysphoric disorder. Dubey N, Hoffman JF, Schuebel K, Yuan Q, Martinez PE, Nieman LK, Rubinow DR, Schmidt PJ, Goldman D. Mol Psychiatry. 2017 Aug;22(8):1172-1184.

5) Efficacy of Transdermal Estradiol and Micronized Progesterone in the Prevention of Depressive Symptoms in the Menopause Transition: A Randomized Clinical Trial. Gordon JL, Rubinow DR, Eisenlohr-Moul TA, Xia K, Schmidt PJ, Girdler SS. JAMA Psychiatry. 2018 Feb 1;75(2):149-157.

6) Reproductive Steroid Regulation of Mood and Behavior. Schiller CE, Johnson SL, Abate AC, Schmidt PJ, Rubinow DR. Compr Physiol. 2016 Jun 13;6(3):1135-60.

Alan F. Schatzberg, M.D.

1. Williams NR, Heifets BD, Blasey C et al: Attenuation of antidepressants effects of ketamine by opioid receptor antagonism.  American Journal of Psychiatry e-pub, August 29, 2019.

2. Sanacora G, Schatzberg AF. Ketamine: Promising Path or False Prophecy in the Development of Novel Therapeutics for Mood Disorders? Neuropsychopharmacology 2015: 40: 259-267

3. Pecina M, Karp JF, Mathew S et al: Endogenous opioid dysfunction in depression- implications for new therapeutic approaches.  Molecular Psychiatry e pub June 28, 2018

4.  Fava M,  Memisoglu A, This ME et al: Opioid modulation with buprenorphine:samidorphan as adjunctive treatment for inadequate response to antidepressants- a randomized double-blind placebo-controlled trial.  American Journal of Psychiatry, 173: 499-508, 2016.

5.  Griffiths RR, Johnson MW, Carducci MA et al: Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial.  Journal of Psychopharmacology. 2016 Dec;30(12):1181-1197.